Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14762196 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP3A4ALOX15TDP1HTT | |
| SCHEMBL8898161 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP3A4ALOX15TDP1HTT | |
| SCHEMBL4621023 | 0.84 | PRMT5 (0.54) | ALDH1A1CYP3A4ALOX15TDP1HTT | |
| SCHEMBL4621022 | 0.84 | PRMT5 (0.54) | ALDH1A1CYP3A4ALOX15TDP1HTT | |
| SCHEMBL27363176 | 0.79 | ALDH1A1 (0.42) | ALDH1A1TDP1HTTTP53MAPT | |
| SCHEMBL28068351 | 0.79 | ALDH1A1 (0.62) | ALDH1A1CYP3A4ALOX15TDP1HTT | |
| SCHEMBL8991531 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPTKMT2AMAOA | |
| SCHEMBL16052639 | 0.78 | PRMT5 (0.46) | ALDH1A1CYP3A4ALOX15TDP1PRMT5 | |
| SCHEMBL10477956 | 0.78 | PRMT5 (0.46) | ALDH1A1CYP3A4ALOX15TDP1PRMT5 | |
| SCHEMBL10477957 | 0.78 | PRMT5 (0.46) | ALDH1A1CYP3A4ALOX15TDP1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772334-B2 | Crosslinker of reactive functional groups and nonionic metal coordinating structure-containing alkyl or aromatic compound | BASF COATINGS GMBH (DE) | 2010-08-10 | — | — | US | claimed |
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-10-16 | — | — | US | disclosed |
| CN-105999275-A | Adsorption of immunopotentiators to insoluble metal salts | 诺华有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-9365506-B2 | Compounds and compositions as TLR2 agonists | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | IRM LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-8808703-B2 | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-08-19 | — | — | US | disclosed |
| EP-2719395-A1 | Adsorption of immunopotentiators to insoluble metal salts | Novartis AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2480253-B1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | IRM LLC (BM) | 2013-10-17 | — | — | US | disclosed |
| CN-103313725-A | Adsorption of insoluble metal ions by immunopotentiators | NOVARTIS AG | 2013-09-18 | — | — | CN | disclosed |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-03-14 | — | — | US | disclosed |
| US-20120177681-A1 | Formulation of immunopotentiators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-07-12 | — | — | US | disclosed |
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | OXRANE (UK) LTD. (GB) | 2008-09-04 | — | — | US | disclosed |
| US-5622137-A | FOR USE IN TESTING COOKED FOODS | TRANS WORLD SERVICES (US) | 1997-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | TLR2, TLR1, TLR3 | ALDH1A1 4593/4885CYP3A4 4591/4885ALOX15 328/4885 |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | TLR2, TLR4, TLR3 | ALDH1A1 4828/4885CYP3A4 2766/4885ALOX15 144/4885 |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | ALDH1A1 3185/4885CYP3A4 2670/4885ALOX15 1042/4885 |
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | GALE, DERA, GNE | ALDH1A1 663/4885CYP3A4 964/4885ALOX15 870/4885 |
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | CD69, NFATC1, CD209 | ALDH1A1 2724/4885CYP3A4 3090/4885ALOX15 1053/4885 |
| US-20120177681-A1 | Formulation of immunopotentiators | CD69, CD4, ICOS | ALDH1A1 2822/4885CYP3A4 2345/4885ALOX15 415/4885 |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | ALDH1A1 3185/4885CYP3A4 2670/4885ALOX15 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.